Alisporivir

Star0

DB12139InvestigationalSmall molecule

Alisporivir has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C.

Mechanism: Pharmacologically active on Peptidyl-prolyl cis-trans isomerase A
Curator reviewed
Formula / weight: C₆₃H₁₁₃N₁₁O₁₂ · 1216.662 g/mol (avg)
Code names: DEB-025 · DEBIO-025 · UNIL-025

Resolves to

Compound

UNIIVBP9099AA6CAS254435-95-5ChEMBLCHEMBL1651956PubChem11513676

Structure

InChIKeyOLROWHGDTNFZBH-XEMWPYQTSA-NSMILES

CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C

Targets

P62937PPIAP49069CAMLG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alisporivir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account